Antibody Fc variants

US8969526B2 · kind B2 · utility

Assignee

• Roche Glycart AG · CH

Inventors

• Monika Baehner · Munich, DE
• Stefan Jenewein · Ludwigshafen, DE
• Manfred Kubbies · Penzberg, DE
• Ekkehard Moessner · Kreuzlingen, CH
• Tilman Schlothauer

Key dates

• Filing date: Mar 27, 2012
• Grant date: Mar 3, 2015
• Expiry date: Apr 24, 2032

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S435/81
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.